Overview

• Shares jumped 16.4% Wednesday to close at $6.09, with about 69.3 million shares traded versus a 26.9 million average.
• The move followed investor anticipation of potential updates at Chris Gibson’s Oct. 15 AI conference appearance in Dubai.
• Recent coverage spotlighted REC-3565, a Phase 1 MALT1 inhibitor that Recursion says emerged from its AI platform.
• In the second quarter, Recursion beat on revenue at $19.22 million but posted a wider loss of $0.41 per share than expected.
• The company cut roughly 20% of staff in June to extend its cash runway into the fourth quarter of 2027 as prominent commentators continue to press for proof of concept.